| |
|
|
| Company Profile | |
| |
|
Research Development |
|
|
| Pipeline | |
| |
| Management Team | |
| |
| Board of Directors | |
| |
| Scientific Advisory Board | |
| |
| Contact Us | |
|
||||
|
|
Home / Company Information / Company Profile / | ||
|
||||
|
Development |
 |
||
|
In systemic lupus erythematosus (SLE), there is an obvious and compelling need for new medications that have fewer and less severe side effects. Genelabs has been dedicated since 1993 to developing a new treatment for women with SLE. These efforts resulted in the submission of a new drug application (NDA) to the Food and Drug Administration (FDA) for which we received an approvable letter in August 2002. In addition, Genelabs has granted an exclusive worldwide license to GlaxoSmithKline Biologicals (GSK) for vaccine applications under Genelabs' HEV patent portfolio. A Phase II clinical trial of an investigational new vaccine candidate has been completed by GSK and published in the New England Journal of Medicine, as described in the following press release: © Genelabs Technologies, Inc. All rights reserved. - Terms of Use |